SCHEMBL2576252

SCHEMBL2576252

Nc1ccc(-c2nc3cc(N4CCN(CCO)CC4)ccc3[nH]2)cc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 6/20 0.58
TOP1 P11387 2/20 0.46
TOP2A P11388 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ACHE P22303 1/20 0.46
DRD2 P14416 5/20 0.42
DRD3 P35462 4/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
SLCO2B1 O94956 1/20 0.42
GLA P06280 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
BCL2L1 Q07817 1/20 0.42
SLCO1B3 Q9NPD5 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14892180 0.88 TERT (0.54) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL14892484 0.87 TERT (0.48) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL12286935 0.86 MAPT (0.53) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL1551571 0.85 ALDH1A1 (0.58) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL14669385 0.84 ALDH1A1 (0.57) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL14892811 0.82 ALDH1A1 (0.54) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL14892671 0.81 ALDH1A1 (0.43) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL14669422 0.81 PARP1 (0.44) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL2554887 0.81 LGMN (0.48) TERTTOP1TOP2AALDH1A1SMN1; SMN2
SCHEMBL14665724 0.81 TERT (0.49) TERTTOP1TOP2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46943-E1 Radioprotector compounds and methods PETER MACCALLUM CANCER INSTITUTE (AU) 2018-07-10 US disclosed
EP-2556058-B1 RADIOPROTECTOR COMPOUNDS AND METHODS PETER MACCALLUM CANCER INST (AU) 2017-06-14 EP disclosed
US-8999993-B2 Radioprotector compounds and methods PETER MACCALLUM CANCER INSTITUTE (AU) 2015-04-07 US disclosed
US-20130109678-A1 RADIOPROTECTOR COMPOUNDS AND METHODS PETER MACCALLUM CANCER INSTITUTE (AU) 2013-05-02 US disclosed
EP-2556058-A1 RADIOPROTECTOR COMPOUNDS AND METHODS Peter MacCallum Cancer Institute (AU) 2013-02-13 EP disclosed
WO-2011123890-A1 RADIOPROTECTOR COMPOUNDS AND METHODS PETER MACCALLUM CANCER INSTITUTE (AU) 2011-10-13 WO disclosed
WO-2011123890-A1 RADIOPROTECTOR COMPOUNDS AND METHODS PETER MACCALLUM CANCER INSTITUTE (AU) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109678-A1 RADIOPROTECTOR COMPOUNDS AND METHODS NR1H2, NR1H3, NR1I3 TERT 2537/4885TOP1 132/4885TOP2A 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.